FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPYbroad
MYCureX · Horizon Europe grant · 2023-07-01–2025-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite recent advances, cancer therapies remain ineffective and/or highly toxic. Our approach is targeting MYC, a function essential to cancer cells that allows them to survive and develop resistance to therapy. In contrast to standard drugs, inhibiting MYC selectively blocks tumor progression without causing important side effects. MYC has been considered undruggable for a long time, and no clinical MYC inhibitor is yet marketed. Peptomycs first-in-class drug, OMO-103, is a cell-penetrating mini-protein that derives from Omomyc, the best MYC inhibitor known to date. OMO-103 recently completed a Phase 1 clinical trial that confirmed its safety and clinical activity in all-comers solid tumor patients, causing a 49% tumor shrinkage in a PDAC patient and stabilizing the disease of 8 out of 12 evaluable patients. Moreover, using AI we identified a predictive and a pharmacodynamic circulating biomarker signatures, and generated companion diagnostic for stratification and real-time response monitoring tests for OMO-103. OMO-103 and its companion diagnostic tests offer a promising therapeutic option for a disease in great need and could apply to treat many other cancer indications. The next steps and goals of this MYCureX project consist of conducting a Phase 1b trial in 1st-line PDAC patients, combining OMO-103 with the standard of care, to evaluate its safety and clinical activity; refining the companion diagnostic prototypes and app; securing the scale-up of the innovation by developing a commercial-scale compatible manufacturing process; and expand the applications of OMO-103 and Peptomyc's drug pipeline. By completing MYCureX, Peptomyc will consolidate the therapeutic potential of MYC inhibition in cancer patients, improving their survival and quality of life while establishing itself as a European leader biotech in MYC targeting.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| PEPTOMYC SL | ES | coordinator | €2,494,504 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.